New scan could spot hidden prostate cancer spread
NCT ID NCT01543659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new type of PET scan using a radioactive tracer called 89Zr-DFO-huJ591 to find prostate cancer that has spread to other parts of the body. 77 men with metastatic prostate cancer received the experimental scan, and some also had standard scans and biopsies for comparison. The goal was to see if the new scan is safe and accurate at detecting cancer sites, especially in bones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
89Zr-DFO-huJ591 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a more accurate way to detect metastatic prostate cancer, helping doctors choose better treatments.
What could go wrong
This is an early-phase study with only 77 participants. The new scan may not be more accurate than existing methods, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States